When: Friday, August 11, 2023 8:30 AM
LifeAire Systems has emerged as a pioneering force in air purification technology driven initially by the critical need to protect human embryos in In Vitro Fertilization (IVF) laboratories. Dr. Kathryn C. Worrilow, a leading embryologist and the company’s founder, dedicated over 20 years to researching the factors impacting IVF outcomes, pinpointing the negative influence of ambient air on embryogenesis. Facing an absence of a suitable air purification solution in the market and recognizing the negative impact air quality exerted on successful IVF outcomes, Dr. Worrilow and her team developed a transformational patented multi-stage system that effectively eliminates airborne chemical and biological pathogens, enabling IVF laboratories to regain control over their processes and achieve remarkable success rates.
Launching first in IVF, programs using LifeAire’s technology have collectively experienced an average 14.9% increase in clinical pregnancy rates. The consistent delivery of the LifeAire technology and statistically significant impact on improved clinical outcomes has positioned the technology as the gold standard in IVF.
Because the technology was initially designed to protect the human embryo, the design criteria was set extraordinarily high. The design goals of the technology included delivering chemical (volatile organic compounds) and biological (bacterial, viral, fungal) pathogens near below detection levels on a single pass through the system without producing byproducts, thus setting a new standard for air purification. Choosing the most difficult biological to kill, the anthrax spore, as the target, the kill technology used in the LifeAire System was tested by the National Homeland Security Research Center in its ability to remediate anthrax. By remediating the anthrax spore, the technology delivers a 9-log kill of all infectious bacteria, viruses and fungi, many of which are responsible for causing illness and infection in the healthcare and senior living setting s.
Through two independent IRB-approved clinical studies, the LifeAire technology was proven to deliver a 98.8% reduction in infectious airborne pathogens and an 88.9% reduction in surface pathogens as compared to HEPA filtration, reduced hospital-acquired infections (HAIs) and readmission rates, shortened patient length of stay, improved healthcare economics with substantial cost savings, a significant reduction in staff callouts, and enhanced hospital throughput and capacity.
LifeAire’s impact, assessed through real-world operational clinical studies, has been published in peer reviewed journals including but not limited to the Journal of Surgery, Journal of Gerontology, Journal of Global Infectious Diseases, ASHRAE Journal, and Vignettes in Patient Safety, providing evidence-based support for the transformational impact of the LifeAire Systems’ technology, one establishing a paradigm shift in the significance of the clinical environment towards patient and resident wellness.
The impact and success of the LifeAire System has prompted leading institutions to implement the technology, including the Mayo Clinic, Stanford University Medical Center, Northwestern University Medical Center, University of Connecticut Health Center, University of Iowa Hospital, Yale University Medical Center, Duke University Medical Center, UCSF Medical Center, Wake Forest Medical Center, University of Massachusetts, and others.
With an unwavering commitment to enabling healthcare institutions to deliver the highest quality of care to the patients they serve, LifeAire Systems has earned its reputation as the gold standard in air purification for the most demanding environments in the world with new opportunities continually emerging in healthcare, senior living, life sciences, commercial applications, and beyond.